Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 36 clinical trials
Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell Disease (SUN)

This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a

hemoglobin c disease
chest syndrome
hydroxyurea
transcranial doppler ultrasonography
priapism
  • 21 views
  • 10 Mar, 2022
  • 6 locations
Preservation and Transfer of HBV Immunity After Allogeneic HSCT for SCD. (PROTECT)

We hypothesize, that sickle cell disease (SCD) patients ending with mixed mononuclear chimerism after non-myeloablative HSCT with alemtuzumab/TBI conditioning will preserve their immune response

alemtuzumab
  • 0 views
  • 25 Mar, 2022
  • 1 location
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor (Sickle-AID)

sickle cell disease (SCD) who have a matched related major ABO-incompatible donor. The nonmyeloablative regimen will use alemtuzumab, total body irradiation (TBI) and sirolimus for immune suppression

osteonecrosis
hydroxyurea
sickle hemoglobin
priapism
splenic sequestration
  • 9 views
  • 26 Jan, 2022
  • 1 location
Islet Cell Transplant for Type 1 Diabetes (TCD)

produce insulin, which can improve blood sugar control and eliminate the need to inject insulin or use an insulin pump. Anti-thymocyte globulin (ATG) and alemtuzumab (Campath) are anti-rejection

immunosuppression
hypoglycemia
mycophenolate mofetil
ketoacidosis
pancreatic islet transplantation
  • 838 views
  • 21 Mar, 2022
  • 1 location
Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders (RIC)

This is a Phase II pilot study to evaluate engraftment and toxicity of patients with non-malignant diseases using a reduced intensity conditioning regimen in the setting of allogeneic transplant for non malignant diseases. Bone Marrow or cord blood will be acceptable as a stem cell source. Recently, reduced intensity conditioning …

reduced intensity conditioning
bone marrow failure
mycophenolate mofetil
campath
severe combined immunodeficiency
  • 1 views
  • 08 Apr, 2022
  • 1 location
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.

osteonecrosis
chest syndrome
hydroxyurea
reduced intensity conditioning
nephropathy
  • 18 views
  • 07 Mar, 2022
  • 2 locations
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

Background Sickle cell disease (SCD) is an inherited disorder of the blood. It can damage a person s organs and cause serious illness and death. A blood stem cell transplant is the only potential cure for SCD. Treatments that improve survival rates are needed. Objective To find out if a …

plerixafor
hydroxyurea
Accepts healthy volunteers
thalassemia
cell transplantation
  • 0 views
  • 27 Jul, 2022
  • 1 location
High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease

Chronic granulomatous disease (CGD) affects white blood cell function. Currently, the only curative treatment is bone marrow transplant to replace the abnormal stem cells with new ones (donor cells) capable of making a normal immune system. Transplant problems include graft versus host disease (GvHD) and graft rejection. With GvHD, donor …

  • 3 views
  • 14 Sep, 2022
  • 1 location
PK Study in Diabetic Transplant r cipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus

The investigators believe that the pharmacological properties of Envarsus, well studied in kidney transplantation, may be also suitable after simultaneous kidney and pancreas transplantation than Prograf. Indeed, Envarsus has demonstrated a clinical efficacy and safety in a complete clinical development plan. This study is to establish the pharmacokinetic profile of …

pancreas transplantation
immunosuppression
end-stage renal disease
tacrolimus
chronic kidney disease (ckd)
  • 0 views
  • 16 Aug, 2021
  • 1 location
Reduced Intensity Transplantation for Severe Sickle Cell Disease

This study is being done to test a transplant method that may have fewer side effects (or less toxic, less harmful) than conventional high dose chemotherapy conditioning-based transplants for children and young adults with Sickle Cell Disease (SCD). Patients less than or equal to 25 years old with SCD who …

plerixafor
chest syndrome
hydroxyurea
sickle cell trait
priapism
  • 0 views
  • 29 May, 2022
  • 1 location